- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-GATA4 monoclonal antibody
Pre-made anti-GATA4 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to GATA4/GATA4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T51817-Ab-1/ GM-Tg-hg-T51817-Ab-2 | Anti-Human GATA4 monoclonal antibody | Human |
| GM-Tg-rg-T51817-Ab-1/ GM-Tg-rg-T51817-Ab-2 | Anti-Rat GATA4 monoclonal antibody | Rat |
| GM-Tg-mg-T51817-Ab-1/ GM-Tg-mg-T51817-Ab-2 | Anti-Mouse GATA4 monoclonal antibody | Mouse |
| GM-Tg-cynog-T51817-Ab-1/ GM-Tg-cynog-T51817-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GATA4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T51817-Ab-1/ GM-Tg-felg-T51817-Ab-2 | Anti-Feline GATA4 monoclonal antibody | Feline |
| GM-Tg-cang-T51817-Ab-1/ GM-Tg-cang-T51817-Ab-2 | Anti-Canine GATA4 monoclonal antibody | Canine |
| GM-Tg-bovg-T51817-Ab-1/ GM-Tg-bovg-T51817-Ab-2 | Anti-Bovine GATA4 monoclonal antibody | Bovine |
| GM-Tg-equg-T51817-Ab-1/ GM-Tg-equg-T51817-Ab-2 | Anti-Equine GATA4 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T51817-Ab-1/ GM-Tg-hg-T51817-Ab-2; GM-Tg-rg-T51817-Ab-1/ GM-Tg-rg-T51817-Ab-2; GM-Tg-mg-T51817-Ab-1/ GM-Tg-mg-T51817-Ab-2; GM-Tg-cynog-T51817-Ab-1/ GM-Tg-cynog-T51817-Ab-2; GM-Tg-felg-T51817-Ab-1/ GM-Tg-felg-T51817-Ab-2; GM-Tg-cang-T51817-Ab-1/ GM-Tg-cang-T51817-Ab-2; GM-Tg-bovg-T51817-Ab-1/ GM-Tg-bovg-T51817-Ab-2; GM-Tg-equg-T51817-Ab-1/ GM-Tg-equg-T51817-Ab-2 |
| Products Name | Anti-GATA4 monoclonal antibody |
| Format | mab |
| Target Name | GATA4 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-GATA4 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T51817-Ag-1 | Recombinant multi-species GATA4/ ASD2/ TACHD protein |
| ORF Viral Vector | vGMAD000115 | human GATA4 Adenovirus particle |
| ORF Viral Vector | pGMAD000115 | human GATA4 Adenovirus plasmid |
| ORF Viral Vector | pGMLV000028 | rat Gata4 Lentivirus plasmid |
| ORF Viral Vector | pGMAAV000160 | rat Gata4 AAV plasmid |
| ORF Viral Vector | pGMAAV000209 | house mouse Gata4 AAV plasmid |
| ORF Viral Vector | pGMAAV000268 | house mouse Gata4 AAV plasmid |
| ORF Viral Vector | pGMLPm004341 | mouse Gata4 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000028 | rat Gata4 Lentivirus particle |
| ORF Viral Vector | vGMAAV000160 | rat Gata4 AAV particle |
| ORF Viral Vector | vGMAAV000209 | house mouse Gata4 AAV particle |
| ORF Viral Vector | vGMAAV000268 | house mouse Gata4 AAV particle |
| ORF Viral Vector | vGMLPm004341 | mouse Gata4 Lentivirus particle |
Target information
| Target ID | GM-T51817 |
| Target Name | GATA4 |
| Gene ID | 2626,14463,54254,696775,486079,101086140,327716,100065126 |
| Gene Symbol and Synonyms | ASD2,Gata-4,GATA4,TACHD,TOF,VSD1 |
| Uniprot Accession | P43694,P46152,Q0Q0E4 |
| Uniprot Entry Name | GATA4_HUMAN,GATA4_RAT,GATA4_CANLF |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | Head and Neck Cancer |
| Gene Ensembl | ENSG00000136574 |
| Target Classification | N/A |
The target: GATA4, gene name: GATA4, also named as ASD2, TACHD, TOF, VSD1. This gene encodes a member of the GATA family of zinc-finger transcription factors. Members of this family recognize the GATA motif which is present in the promoters of many genes. This protein is thought to regulate genes involved in embryogenesis and in myocardial differentiation and function, and is necessary for normal testicular development. Mutations in this gene have been associated with cardiac septal defects. Additionally, alterations in gene expression have been associated with several cancer types. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
